• Weekly Pharma News Review | PharmaSources.com (0130-0203) PharmaSources.com
    February 06, 2023
    NMPA announced the emergency drug review and approval, and conditionally approved the first-in-class innovative drugs, Simnotrelvir Tablets/Ritonavir Tablets of Hainan Simcere Pharmaceutical and Renmindevir of Shanghai Wangshi Biological Technology.
PharmaSources Customer Service